Cambridge-based health tech company Qureight has secured $8.5m (£6.8m) in funding to further develop its digital infrastructure aimed at handling complex medical data.
Founded in response to limited treatment options for heart and lung diseases, Qureight addresses the challenge of manually extracting crucial information from vast datasets, which is both time-consuming and costly.
Qureight identifies a critical issue in the healthcare sector: the manual extraction of vital information from extensive medical data sets. This process not only consumes valuable time but also incurs significant expenses.
Additionally, the limited treatment options for complex heart and lung diseases highlight the urgent need for innovative solutions in the medical field.
Qureight offers an AI-powered platform designed to automate the extraction and structuring of medical data in real time. Through partnerships with the NHS, Qureight streamlines the process of data collation, making it readily available for analysis.
Moreover, the structured data facilitates the creation of virtual trial patients, enhancing research capabilities and expediting medical discoveries.
Qureight’s solution targets healthcare professionals, researchers, and pharmaceutical companies involved in the treatment and research of complex heart and lung diseases.
By providing advanced tools to streamline data management and analysis, Qureight aims to empower its users to accelerate the discovery of new treatments and improve patient outcomes.
The company’s innovative approach to leveraging AI technology resonates with investors and partners seeking opportunities to revolutionize healthcare through data-driven solutions.